Akarna Therapeutics is a biopharmaceutical company developing novel small molecule therapeutics that target inflammatory and fibrotic diseases. Akarna’s lead program is a potential best-in-class therapeutic for the treatment of non-alcoholic steatohepatitis (NASH). On August 26, 2016 Akarna was acquired by Allergan for an USD 50m upfront cash payment and success-based development, approval and sales milestone payments.
Employees: 11-50
Total raised: $15M
Founded date: 2014
Investors 2
| Date | Name | Website |
| - | Forbion | forbion.co... |
| - | Third Poin... | thirdpoint... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.02.2016 | Series B | $15M | Forbion |
Mentions in press and media 5
| Date | Title | Description | Source |
| 21.09.2016 | Allergan Acquires Akarna Therapeutics, for $50M | Allergan plc., (NYSE: AGN), acquired Akarna Therapeutics Ltd., a Cambridge, UK-based biopharmaceutic... | finsmes.co... |
| 16.02.2016 | Akarna Therapeutics Gets $15M | San Diego- and Cambridge, England-based Akarna Therapeutics Ltd. announced this morning that it has ... | socaltech.... |
| 16.02.2016 | Forbion invests in Akarna Therapeutics $15 Million Series B ... | Forbion Capital Partners (“Forbion”), one of the leading Dutch Venture Capital firms investing in wo... | forbion.co... |
| 16.02.2016 | Akarna Therapeutics Closes $15M Series B Financing | Akarna Therapeutics Ltd., a Cambridge, UK- and Encinitas, California-based biopharmaceutical company... | finsmes.co... |
| 16.02.2016 | Akarna Therapeutics Lands $15M | SAN DIEGO, CA, Akarna Therapeutics, a privately held biopharmaceutical company, today announced th... | vcnewsdail... |